NCT00377598 - Efficacy, Safety and Tolerability Study of TAK-583 in Subjects With Postherpetic Neuralgia | Biotech Hunter

Enrollment

399

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions

Neuralgia, Postherpetic

Interventions

DRUG

TAK-583

TAK-583 5 mg, tablets, orally, once daily for up to 8 weeks

DRUG

TAK-583

TAK-583 25 mg, tablets, orally, once daily for up to 8 weeks

DRUG

TAK-583

TAK-583 50 mg, tablets, orally, once daily for up to 8 weeks

DRUG

TAK-583

TAK-583 100 mg, tablets, orally, once daily for up to 8 weeks

DRUG

Placebo

TAK-583 placebo-matching tablets, orally, once daily for up to 8 weeks

Trial Locations (48)

Unknown

Sydney

Kipparing

Maroochydore

Box Hill

Carlton

Fitzroy

Perth

Sofia

Hradec Králové

Moravská Ostrava

Olomouc

Ostrava

Pilsen

Berlin

Dresden

Frankfurt

Görlitz

Hamburg

Jena

Leipzig

Magdeburg

Schwerin

Arnhem

Breda

Roosendaal

Rotterdam

Stadskanaal

Utrecht

Gdansk

Lublin

Mosina k/Poznania

Poznan

Kazan'

Moscow

Saint Petersburg

Bloemfontein

Pretoria

Amanzimtori

Durban

Breyten

Mbombela

Polokwane

Worcester

Chichester

Darlington

Glasgow

Plymouth

Solihull